Stockreport

Fractyl Health: Unreasonably Low Market Expectations Create A Trading Opportunity Towards 2026 Catalysts [Seeking Alpha]

Fractyl Health, Inc.  (GUTS) 
PDF Revita's pivotal Phase 3 obesity trial is well-funded, with topline results expected in 2H 2026 and a low statistical bar for success. Weight regain in the Revita arm [Read more]